Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 10 2024 - 2:00AM
Press Release: Sanofi and Novavax announce co-exclusive licensing
agreement to co-commercialize COVID-19 vaccine and develop novel
flu-COVID-19 combination vaccines
Sanofi and Novavax announce co-exclusive licensing
agreement to co-commercialize COVID-19 vaccine and develop novel
flu-COVID-19 combination vaccines
- Agreement provides patients with broader access to a
protein-based non-mRNA adjuvanted COVID-19 vaccine through combined
commercial strength, from 2025 onwards
- Accelerates potential for development of a novel flu-COVID-19
combination product based on authorized vaccines with demonstrated
efficacy and tolerability, potentially offering patients enhanced
convenience and protection
Paris and Gaithersburg, Md., United States. May 10,
2024. As part of Sanofi’s commitment to developing a
diverse portfolio of best-in-class vaccines, the company has
entered into a co-exclusive licensing agreement with Novavax, a
biotechnology company headquartered in Maryland, US.
The terms of the agreement include: a co-exclusive license to
co-commercialize Novavax’s current stand-alone adjuvanted COVID-19
vaccine worldwide (except in countries with existing Advance
Purchase Agreements and in India, Japan, and South Korea where
Novavax has existing partnership agreements); a sole license to
Novavax’s adjuvanted COVID-19 vaccine for use in combination with
Sanofi’s flu vaccines; and a non-exclusive license to use the
Matrix-M adjuvant in vaccine products. In addition, Sanofi will
take a minority (<5%) equity investment in Novavax.
Jean-Francois ToussaintGlobal Head of Vaccines
R&D“With flu and COVID-19 hospital admission rates now closely
mirroring each other, we have an opportunity to develop non-mRNA
flu-COVID-19 combination vaccines offering patients both enhanced
convenience and protection against two serious respiratory viruses.
We’re excited by the prospect of combining Novavax’s adjuvanted
COVID-19 vaccine that has shown high efficacy and favorable
tolerability, with our rich portfolio of differentiated flu
vaccines that have demonstrated superior protection against flu and
its serious complications. Improved tolerability and
thermostability, without compromise on efficacy, are what
regulators, recommending bodies, and patients will demand.”
John JacobsCEO, Novavax
“This collaboration is important for Novavax and
for global public health. Our new partnership combines Novavax’s
proprietary recombinant protein and nanoparticle technologies,
Matrix™ adjuvant, and R&D expertise with Sanofi’s world-class
leadership in launching and commercializing innovative vaccines.
Together, we can broaden access to both our COVID-19 vaccine and
our adjuvant to ensure more individuals can benefit from the
protection vaccines can provide. Novavax is now in a stronger
position to refocus our efforts on leveraging our technology
platform and novel adjuvant in research and development and
pipeline expansion to help advance our mission of developing
life-saving vaccines to fight infectious diseases.”
Under the terms of the licensing agreement:
- Novavax will receive an upfront payment of $500 million
and up to $700 million in
development, regulatory and launch milestones, up to
$1.2 billion in total.
- Starting in 2025, Sanofi will book sales of Novavax’s
adjuvanted COVID-19 vaccine and will support certain R&D,
regulatory, and commercial expenses.
- Novavax will receive tiered double-digit percentage royalty
payments on sales by Sanofi of COVID-19 vaccines and flu-COVID-19
combination vaccines.
- Sanofi will be solely responsible for development and
commercialization of any novel flu-COVID-19 combination vaccine
containing a Sanofi flu vaccine.
- Outside of the collaboration, each party may develop and
commercialize their own flu-COVID-19 vaccines and adjuvanted
products at their own cost.
- Novavax is entitled to additional launch and sales
milestones opportunities of up to $200 million plus mid-single
digit royalties for each additional Sanofi vaccine product
developed under a non-exclusive license with Novavax’s Matrix-M
adjuvant technology.
- In addition, Sanofi will take a minority (<5%) equity
investment in Novavax.
About NovavaxNovavax, Inc. (Nasdaq: NVAX)
promotes improved health by discovering, developing and
commercializing innovative vaccines to help protect against serious
infectious diseases. Novavax, a global company based in
Gaithersburg, Md., U.S., offers a differentiated vaccine platform
that combines a recombinant protein approach, innovative
nanoparticle technology and Novavax's patented Matrix-M adjuvant to
enhance the immune response. The Company's portfolio includes its
COVID-19 vaccine, and its pipeline includes CIC and stand-alone
influenza vaccine candidates. In addition, Novavax's adjuvant is
included in the University of Oxford and Serum Institute of India's
R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn
for more.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions.Sanofi is
listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine Guendoul | + 33 6 25 09
14 25 | sandrine.guendoul@sanofi.comSally Bain | +
1 617 834 6026 | sally.bain@sanofi.comEvan Berland
| + 1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | + 33
6 77 21 27 55 | nicolas.obrist@sanofi.com
Investor RelationsThomas Kudsk Larsen |+ 44
7545 513 693 | thomas.larsen@sanofi.comAlizé
Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains
forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These
statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions,
and expectations with respect to future financial results, events,
operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar
expressions. Although Sanofi’s management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2023. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Sanofi (EU:SAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2023 to Sep 2024